Komagome PROGRES Project
- Conditions
- Malignant lymphomas, Solid tumorsMalignant lymphoma
- Registration Number
- JPRN-jRCT1030190169
- Lead Sponsor
- Shimoyama Tatsu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Subject must satisfy the inclusion criteria (4.3.2) among the subjected patients (4.3.1) and do not meet any of the exclusion criteria.
4.3.1 Subjected patient
Patients with malignant lymphoma or solid cancer* treated in Tokyo Metropolitan Komagome Hospital (* stomach cancer, colon cancer, pancreatic cancer, gallbladder cancer, bile duct cancer, head and neck cancer, etc.)
4.3.2 Inclusion criteria
Subject is 20 years or older of age at the time of obtaining consent.
Histologically or cytologically proven malignant tumor.
Subject must understand and voluntarily sign the informed consent form after receiving sufficient explanation for participation in this study
Subject who has complicated psychiatric illness or symptoms that interfere with daily life and is considered difficult to participate in the study
Subject who has any medical condition that would prevent the subject from participating in the study based on investigator's judgment.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate at which any genetic abnormality is detected<br><br>Percentage of each gene abnormality
- Secondary Outcome Measures
Name Time Method umber of somatic cell line mutations and mutation rate in exons<br><br>Positive rate of biomarkers (things that are directly related to therapeutic drugs/treatment methods)<br><br>Treatment options after oncogene panel testing<br><br>Objective response rate (including correlation between biomarker and therapeutic response)<br><br>Disease control rate<br><br>Overall survival and progression free survival<br><br>Number of germline mutations suspected and confirmed by Sanger sequencing